Prostate cancer (PCa) is the most prevalent solid organ malignancy and seriously affects
male health. The adverse effects of prostate cancer therapeutics can cause secondary …

In the present study, we investigated the synergistic effects of targeted methotrexate-
selenium nanostructure containing Myc decoy oligodeoxynucleotides along with X …

Highlights•PSMA is a transmembrane glycoprotein highly expressed in prostate cancer
(PC).•PSMA PET-CT is revolutionising PC management in staging and biochemical …

Prostate-specific membrane antigen (PSMA)-targeted radio ligand therapeutics (RLTs), such
as [177Lu] Lu-PSMA-617 (Pluvicto), have been shown to accumulate in salivary glands and …

Prostate cancer (PCa) is one of the most common tumors in men, with the overexpression of
prostate-specific membrane. In this study, we developed four new 68 Ga-labeled PSMA …

Background Tumor initiation and progression necessitate a metabolic shift in cancer cells.
Consequently, the progression of prostate cancer (PCa), a leading cause of cancer‐related …

Radionuclide probes-targeted prostate-specific membrane antigen (PSMA) is used in
diagnosis and treatment of prostate cancer (PCa). Recent studies have shown that PSMA is …

Aim The early detection of prostate cancer (PCa) metastatic disease with PET imaging leads
to stage migration and change of disease management. We aimed to assess the impact on …

Background: Prostate-specific membrane antigen (PSMA) is an ideal target for molecular
imaging and targeted radionuclide therapy in prostate cancer. Consequently, various PSMA …

According to the World Health Organization (WHO)," cancer is a leading cause of death
worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths"[1] …